Navigation Links
Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
Date:11/22/2011

BOSTON, Nov. 22, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) is pleased to announce that it finished the 3rd Quarter with a Net Profit of $73,895.  Solos Endoscopy has consummated agreements which resulted in the Forgiveness of debt of $299,082 for the Three Months period ending September 30, 2011.  The signed settlement agreement and new consulting agreement result in a reduction of ongoing expenses by approximately $40,000 per quarter.

Solos Endoscopy posted its financial statements for period ended September 30, 2011.  While the Company saw a modest decrease in sales over the three month period, the Net Profit is a result of Management's cost cutting and debt reduction efforts.  Management is extremely pleased with the increase in demand for its new MammoView® instrument line.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"Solos management has worked extremely hard to position the Company for future success.  This is represented by our tireless efforts to work with our creditors, while remaining focused on future product development. We have allocated significant resources to the development of the MammoView® instrument line.  The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is truly amazing.  I'd like to thank the shareholders for all their continued support," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please visit http://www.otcmarkets.com/stock/SNDY/financials for more information.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact: Amanda Segersten, rsegersten@solosendoscopy.com


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
2. Solos Endoscopy Goes Google
3. Solos Endoscopy Finishes the 3rd Quarter Strong
4. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
5. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
6. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
7. Solos Endoscopy to Reduce Debt by Over $620,000
8. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
9. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
10. Solos Endoscopy, Inc. To Launch New Corporate Website
11. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):